Matthew Pillar
Chief Editor at Bioprocess Online
Host at Business Of Biotech
Host, Business of Biotech Podcast. Editor, Bioprocess Online. I like it better on LinkedIn -- follow me there! https://t.co/7rwRY0AdUD
Articles
-
2 months ago |
cellandgene.com | Matthew Pillar |Raul P. Lima |inSeption Group |Lakshmi Guduri
Join Cell & Gene Live for an exclusive look at cutting-edge manufacturing technologies revolutionizing cell therapy production. Our expert panel will explore organoids, 3D cultures, automation, and scalable solutions to streamline processes and enhance efficiency. Gain insights into the latest innovations driving the future of cell therapy. Registration is free thanks to the support of CPC and MaxCyte.
-
Dec 3, 2024 |
bioprocessonline.com | Matthew Pillar
By Matthew Pillar, Editor, Bioprocess Online COUR Pharmaceuticals has been, as its newly-appointed President & CEO Dannielle Appelhans puts it, flying under the radar for a long time. COUR made a splash back in 2015, when it formed up around a biodegradable nanoparticle encapsulating gliadin proteins that proved to reverse the effects of gluten in animal models.
-
Oct 30, 2024 |
bioprocessonline.com | Matthew Pillar
By Matthew Pillar, Editor, Bioprocess Online Way back in November 2021, Cidara Therapeutics entered into a collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of J&J, to advance the development of Cidara’s lead drug-Fc conjugate (DFC), a compound called CD388 that was pre-clinical at the time.
-
Oct 17, 2024 |
bioprocessonline.com | Matthew Pillar
By Matthew Pillar, Editor, Bioprocess Online Lexeo Therapeutics VP of Analytical Development & Quality Timothy Fenn, Ph.D. took the stage at the ribbon cutting ceremony for MilliporeSigma’s new $3.2 million biosafety testing facility in Rockville, Maryland last week.
-
Oct 17, 2024 |
biosimilardevelopment.com | Matthew Pillar
By Matthew Pillar, Editor, Bioprocess Online Lexeo Therapeutics VP of Analytical Development & Quality Timothy Fenn, Ph.D. took the stage at the ribbon cutting ceremony for MilliporeSigma’s new $3.2 million biosafety testing facility in Rockville, Maryland last week.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 606
- DMs Open
- No
RT @Bob_Hetu: Retailers increasingly not accepting #cash in the US market. The excuse is a lack of circulation of cash due to #COVID19 doe…
I really leaned in to @Allan_L_Shaw's #startup financing knowledge base for this candid conversation on the ins and outs of a special purpose acquisition company, or #SPAC, as a biopharma finance vehicle. He was definitely the man to ask. Via BioProcess O…https://t.co/zCe4290TDG
Want to know what process intensification is, the results it drives, the challenges it presents, and how to implement it in your upstream #bioprocessing environment? Join Sonnet BioTherapeutics, Inc. CTO Susan Dexter, single-use an…https://t.co/VlUpKKHnfx https://t.co/VCVehGRscA